Get the Stockscreener App
14.93
1.65%
-0.25
After Hours:
15.12
0.19
+1.27%
Biodesix Inc stock is traded at $14.93, with a volume of 30,178.
It is down -1.65% in the last 24 hours and up +28.93% over the past month.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
See More
Previous Close:
$15.18
Open:
$15.04
24h Volume:
30,178
Relative Volume:
0.32
Market Cap:
$150.92M
Revenue:
$88.50M
Net Income/Loss:
$-35.27M
P/E Ratio:
-4.5306
EPS:
-3.2954
Net Cash Flow:
$-23.70M
1W Performance:
+5.36%
1M Performance:
+28.93%
6M Performance:
+118.59%
1Y Performance:
+109.75%
1-Day Range:
$14.72
$15.43
1-Week Range:
$13.58
$15.44
52-Week Range:
$5.00
$20.21
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
14.93 | 153.45M | 88.50M | -35.27M | -23.70M | -3.2954 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-26-24 | Initiated | Craig Hallum | Buy |
| May-13-24 | Initiated | TD Cowen | Buy |
| May-03-24 | Initiated | Lake Street | Buy |
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
View All
Biodesix Inc Stock (BDSX) Latest News
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade - Zacks Investment Research
Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions - Insider Monkey
Biodesix (NASDAQ: BDSX) registers 375,000 shares for Perceptive resale - Stock Titan
Biodesix meets investors in Minneapolis, Chicago and Dana Point - Stock Titan
Biodesix to Participate in Upcoming Investor Conferences - Caledonian Record
Biodesix shareholders elect directors and approve executive compensation By Investing.com - Investing.com Australia
Biodesix shareholders elect directors and approve executive compensation - Investing.com
Biodesix Shareholders Approve Directors and Governance Measures - TipRanks
Biodesix (NASDAQ: BDSX) holders back directors, pay and KPMG auditor - Stock Titan
BDSX Stock Price, Quote & Chart | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Perceptive entities disclose 4.6% holding in Biodesix (NASDAQ: BDSX) - Stock Titan
Biodesix BDSX Q2 2025 Earnings Call Transcript - AOL.com
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy - The Manila Times
Blood test for lung nodules gets real-world spotlight at ATS 2026 - Stock Titan
Biodesix to present new real-world data on Nodify Lung testing at ATS 2026, highlighting clinical and economic benefits. - Pluang
Does Biodesix (BDSX) have the potential to rally 103.33% as Wall Street analysts expect? - MSN
Biodesix (NASDAQ: BDSX) holder Soleus reports 416,599 shares (4.1%) - Stock Titan
Biodesix Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q3 2025 Biodesix Inc Earnings Call Transcript - GuruFocus
Number of shareholders of Biodesix, Inc. – NASDAQ:BDSX - TradingView
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect? - Yahoo Finance
Biodesix Earnings Call Signals Strong Growth Momentum - The Globe and Mail
Biodesix Faces Mounting Reimbursement and Enforcement Risks as Evolving Payer Policies Threaten Revenue Stability - TipRanks
TD Cowen Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
MSN Money - MSN
Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price - MarketBeat
Biodesix touts ‘clear path toward profitability’ - BizWest
William Blair Maintains Biodesix(BDSX.US) With Buy Rating - Moomoo
Lake Street Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
CCORF Maintains Biodesix(BDSX.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Biodesix Inc. 10-Q Q1 2026: Financial Statements, Risk Factors, and Management Analysis - Minichart
Biodesix stock price target raised to $22 by Canaccord on revenue growth - Investing.com
Biodesix, Inc. (NASDAQ:BDSX) Q1 2026 Earnings Call Transcript - Insider Monkey
Biodesix (BDSX) Q1 2026 Earnings Transcript - AOL.com
Biodesix, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Biodesix Q1 Earnings Call Highlights - MarketBeat
BDSX Financials: Income Statement, Balance Sheet & Cash Flow | BIODESIX INC - Stock Titan
BDSX: Q1 revenue up 42% year-over-year, with raised 2026 guidance and margin expansion - TradingView
Biodesix Q1 2026 Earnings Call: Complete Transcript - Benzinga
Earnings call transcript: Biodesix Q1 2026 shows revenue growth, stock steady - Investing.com
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Biodesix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Biodesix Inc (NASDAQ:BDSX) Q1 Results Smash Estimates, Shares Jump on Raised Guidance - ChartMill
Biodesix (NASDAQ:BDSX) Announces Earnings Results, Beats Estimates By $0.32 EPS - MarketBeat
Q1 2026 Biodesix Inc Earnings Call Transcript - GuruFocus
Biodesix Announces First Quarter 2026 Results and Highlights - The Manila Times
Biodesix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biodesix Inc Stock (BDSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):